Amanda Paschke

3.5k total citations · 1 hit paper
32 papers, 1.2k citations indexed

About

Amanda Paschke is a scholar working on Epidemiology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Amanda Paschke has authored 32 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Epidemiology, 15 papers in Infectious Diseases and 13 papers in Pharmacology. Recurrent topics in Amanda Paschke's work include Antibiotics Pharmacokinetics and Efficacy (13 papers), SARS-CoV-2 and COVID-19 Research (10 papers) and Antibiotic Resistance in Bacteria (10 papers). Amanda Paschke is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (13 papers), SARS-CoV-2 and COVID-19 Research (10 papers) and Antibiotic Resistance in Bacteria (10 papers). Amanda Paschke collaborates with scholars based in United States, Ukraine and Germany. Amanda Paschke's co-authors include Nicholas A. Kartsonis, Jiejun Du, Michelle Brown, Joan R. Butterton, Michelle Brown, Robert Tipping, Keith S. Kaye, Helen W. Boucher, Katherine Young and Alison Pedley and has published in prestigious journals such as Annals of Internal Medicine, PLoS ONE and PEDIATRICS.

In The Last Decade

Amanda Paschke

28 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

2019 284 citations Helen W. Boucher, Keith S. Kaye et al. Clinical Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amanda Paschke United States	14	657	539	478	343	318	32	1.2k
Alice J. Hsu United States	18	453 0.7×	358 0.7×	402 0.8×	218 0.6×	301 0.9×	41	1.0k
C Andrew DeRyke United States	17	636 1.0×	639 1.2×	401 0.8×	338 1.0×	242 0.8×	60	1.1k
Carlos Roberto Veiga Kiffer Brazil	17	500 0.8×	276 0.5×	337 0.7×	247 0.7×	165 0.5×	63	977
Sutep Jaruratanasirikul Thailand	21	349 0.5×	621 1.2×	633 1.3×	162 0.5×	394 1.2×	58	1.3k
Elizabeth Neuner United States	20	793 1.2×	517 1.0×	612 1.3×	335 1.0×	345 1.1×	53	1.4k
Rupali Jain United States	17	335 0.5×	322 0.6×	419 0.9×	144 0.4×	412 1.3×	55	1.1k
Jiejun Du United States	10	500 0.8×	390 0.7×	275 0.6×	264 0.8×	131 0.4×	22	748
Michael P. Veve United States	17	319 0.5×	272 0.5×	330 0.7×	163 0.5×	305 1.0×	76	925
Yanina Dubrovskaya United States	18	294 0.4×	347 0.6×	368 0.8×	121 0.4×	248 0.8×	52	879
Christina Sutherland United States	21	577 0.9×	712 1.3×	373 0.8×	207 0.6×	217 0.7×	45	1.1k

Countries citing papers authored by Amanda Paschke

Since Specialization

Citations

This map shows the geographic impact of Amanda Paschke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amanda Paschke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amanda Paschke more than expected).

Fields of papers citing papers by Amanda Paschke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amanda Paschke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amanda Paschke. The network helps show where Amanda Paschke may publish in the future.

Co-authorship network of co-authors of Amanda Paschke

This figure shows the co-authorship network connecting the top 25 collaborators of Amanda Paschke. A scholar is included among the top collaborators of Amanda Paschke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amanda Paschke. Amanda Paschke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chawla, Akshita, Ruthie Birger, Brian M. Maas, et al.. (2025). Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID‐19. Clinical and Translational Science. 18(4). e70184–e70184.

Caraco, Yoseph, Matthew G. Johnson, Brian M. Maas, et al.. (2025). Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT study. Clinical Trials. 22(3). 312–324.

Johnson, Matthew G., Julie Strizki, Erin Jensen, et al.. (2024). Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT). Microbiology Spectrum. 12(3). e0356323–e0356323.

Puenpatom, Amy, Matthew G. Johnson, Ying Zhang, et al.. (2023). Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial. Clinical Infectious Diseases. 77(11). 1521–1530. 9 indexed citations

Alpizar, Sady, José Accini, Duane C. Anderson, et al.. (2023). Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial. Journal of Infection. 87(5). 392–402. 9 indexed citations

Bradley, John S., Camilla Tøndel, Emmanuel Roilides, et al.. (2023). Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram‐Negative Bacterial Infections: A Phase 1b, Open‐Label, Single‐Dose Clinical Trial. The Journal of Clinical Pharmacology. 63(12). 1387–1397. 6 indexed citations

Roberts, Jason A., David P. Nicolau, Ignacio Martín‐Loeches, et al.. (2023). Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance. JAC-Antimicrobial Resistance. 5(2). dlad011–dlad011. 10 indexed citations

Chawla, Akshita, Ruthie Birger, Hong Wan, et al.. (2023). Factors Influencing COVID‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes. Clinical Pharmacology & Therapeutics. 113(6). 1337–1345. 6 indexed citations

Martín‐Loeches, Ignacio, Andrew F. Shorr, Marin H. Kollef, et al.. (2023). Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis. Open Forum Infectious Diseases. 10(6). ofad225–ofad225. 2 indexed citations

10.

Johnson, Matthew G., Julie Strizki, Michelle Brown, et al.. (2023). Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial. Infection. 51(5). 1273–1284. 23 indexed citations

11.

Strizki, Julie, Jay A. Grobler, Nicholas Murgolo, et al.. (2023). Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial. Infectious Diseases and Therapy. 12(12). 2725–2743. 6 indexed citations

12.

Johnson, Matthew G., Amy Puenpatom, Pablo Andrés Moncada, et al.. (2022). Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19. Annals of Internal Medicine. 175(8). 1126–1134. 44 indexed citations

13.

Arribas, José Ramón, Sanjay Bhagani, Suzana M. Lobo, et al.. (2021). Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19. NEJM Evidence. 1(2). EVIDoa2100044–EVIDoa2100044. 86 indexed citations

14.

Bradley, John S., Camilla Tøndel, Emmanuel Roilides, et al.. (2021). 1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial. Open Forum Infectious Diseases. 8(Supplement_1). S671–S671. 3 indexed citations

15.

Kohno, Shigeru, Hiroyuki Bando, Hiroaki Kikukawa, et al.. (2020). The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study. Journal of Infection and Chemotherapy. 27(2). 262–270. 18 indexed citations

16.

Groll, Andreas H., Hisham Abdel‐Azim, Thomas Lehrnbecher, et al.. (2020). Pharmacokinetics and safety of posaconazole intravenous solution and powder for oral suspension in children with neutropenia: an open-label, sequential dose-escalation trial. International Journal of Antimicrobial Agents. 56(3). 106084–106084. 32 indexed citations

17.

Kaye, Keith S., Helen W. Boucher, Michelle Brown, et al.. (2020). Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections. Antimicrobial Agents and Chemotherapy. 64(5). 19 indexed citations

18.

Arrieta, Antonio, Lillian Sung, John S. Bradley, et al.. (2019). A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia. PLoS ONE. 14(3). e0212837–e0212837. 34 indexed citations

19.

Sims, Matthew, Patrick McLeroth, Yu‐Chieh Lee, et al.. (2017). Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. Journal of Antimicrobial Chemotherapy. 72(9). 2616–2626. 126 indexed citations

20.

Paschke, Amanda, Theoklis Zaoutis, Patrick H. Conway, Dawei Xie, & Ron Keren. (2010). Previous Antimicrobial Exposure Is Associated With Drug-Resistant Urinary Tract Infections in Children. PEDIATRICS. 125(4). 664–672. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact